-
公开(公告)号:US20240400664A1
公开(公告)日:2024-12-05
申请号:US18514269
申请日:2023-11-20
Applicant: AMGEN INC. , UCB PAHRMA S.A.
Inventor: Martyn K. Robinson , Michael S. Ominsky , Xiaodong Li , Hua Zhu Ke
Abstract: The invention relates to the treatment of bone disorders. In particular, the invention provides an approach involving administration of a high initial dose or doses of an sclerostin antibody to bring about a rapid increase in bone formation, followed by administration of lowers doses of the antibody to give a sustained lower rate of bone formation after the initial burst of bone formation. The invention also provides an approach involving decreasing dosing frequency with such an antibody to control bone formation. The approaches may be used in particular in those subjects who would benefit most from such an initial rapid burst of bone formation. Examples of such subjects include subjects who have been recently diagnosed or are experiencing severe symptoms of the disorder, as well as those subjects who have been administered a different treatment for the bone disorder which is proving ineffective. The approaches may be used in combination with each other.
-
公开(公告)号:US20190185556A1
公开(公告)日:2019-06-20
申请号:US16323470
申请日:2017-08-07
Applicant: AMGEN INC. , WASHINGTON UNIVERSITY
Inventor: Michael S. Ominsky , Stavros Thomopoulos
CPC classification number: C07K16/22 , A61K38/00 , A61K39/3955 , A61K2039/505 , A61K2039/545 , A61L27/22 , A61L27/56 , A61P41/00 , C07K2317/76
Abstract: The application provides method for enhancing connective tissue-to-bone healing in a subject in need thereof comprising administering to the subject an anti-sclerostin antibody in an amount effective to enhance connective tissue-to-bone healing in the subject.
-